Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025

HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Accesswire • Dec 8, 2025

Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2026 Earnings Call September 15, 2025 4:30 PM EDT Company Participants Robert Brainin - CEO & Director David Miller - Chief Financial Officer Conference Call Participants George Marema - Pareto Ventures Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2026 Earnings Call.

Seeking Alpha • Sep 15, 2025

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million

This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025.

Accesswire • Sep 15, 2025

Champions Oncology Reports Record Quarterly Revenue of $14.0 Million

Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025. First Quarter and Recent Highlights: Total revenue of $14 million Adjusted EBITDA of $60,000 Appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth Rob Brainin, newly appointed CEO of Champions, commented, "It is great to be joining Champions at such an exciting inflection point.

Accesswire • Sep 15, 2025

Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025

HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ended July 31, 2025, on Monday, September 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Accesswire • Sep 10, 2025

Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript

Champions Oncology (NASDAQ:CSBR ) Q4 2025 Earnings Call July 23, 2025 4:30 PM ET Company Participants David Barry Miller - Chief Financial Officer Ronnie Morris - CEO & Director Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Greetings. Welcome to the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call.

Seeking Alpha • Jul 25, 2025

Champions Oncology Reports Record Annual Revenue of $57 Million

Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025. Fourth Quarter Financial Highlights: Total revenue of $12.3 million Adjusted EBITDA loss of $1.2 million New data licensing revenue of approximately $200,000 Operating cash flow of $6.4 million Fiscal Year 2025 Financial Highlights: Record annual revenue of $57 million, an increase of 14% year-over-year Net income of $4.6 million Adjusted EBITDA income of $7.1 million Data license revenue of $4.7 million Year-end cash balance of $9.8 million Ronnie Morris, CEO of Champions, commented, "This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation".

Accesswire • Jul 23, 2025

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025

HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Accesswire • Jul 21, 2025

Champions Oncology Announces Appointment of New CEO

HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025. Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017.

Accesswire • Jul 18, 2025

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.

Accesswire • Jul 8, 2025